Thursday, 04 June 2026 04:44 PM
Class Action
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2026 / Lifshitz Law Firm
Kyndryl Holdings, Inc. (NYSE:KD)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) Kyndryl's financial statements issued during the Relevant Period were materially misstated; (ii) Kyndryl lacked adequate internal controls and at times materially understated issues with its internal controls; and (iii) as a result of the foregoing, Kyndryl would be unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025.
If you are a KD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
Corcept Therapeutics, Inc. (NASDAQ:CORT)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the strength of the clinical trials supporting relacorilant by representing them as "powerful support" for Corcept's New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA"); (ii) the Company falsely conveyed confidence in relacorilant's regulatory prospects by claiming they had communicated with the FDA, foresaw no impediments to approval, and repeatedly told investors that "relacorilant is approaching approval," when, in fact, the FDA had repeatedly raised concerns regarding the adequacy of the clinical evidence supporting the NDA; and (iii) as a result of the foregoing, the Company failed to disclose the known and material risk that Corcept's relacorilant NDA would not be approved.
If you are a CORT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
NuScale Power Corporation (NYSE:SMR)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) ENTRA1 had never built, financed, or operated any significant projects - let alone projects in the highly technical and complicated field of nuclear power generation - during its entire operating history; (ii) the Company had entrusted its commercialization, distribution, and deployment of its NPMs and hundreds of millions of dollars of NuScale capital to an entity that lacked any significant prior experience owning, financing, or operating nuclear energy generation facilities; (iii) the purported experience and qualifications attributed to ENTRA1 by the Company during the Relevant Period in fact referred to the purported experience and qualifications of the principals of the Habboush Group, a distinct entity without significant experience in the field of nuclear power generation; and (iv) as a result of the foregoing, NuScale's commercialization strategy was exposed to material, undisclosed risks of failure, delays, regulatory challenges, or other negative setbacks.
If you are an SMR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company created the false impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta, while also minimizing risk that patients in Ultragenyx's Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; and (ii) in truth, Ultragenyx's optimism in the Phase III Orbit study's results and interim analysis benchmark were misplaced because Ultragenyx failed to convey the risk associated with basing such threshold figures on Phase II results that had no placebo control group for appropriate comparison and thus had not ruled out that the reduction in AFR from that study could merely be triggered by an increased standard of care and the placebo effect of being provided a novel treatment.
If you are an RARE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].
ATTORNEY ADVERTISING.© 2026 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: [email protected]
SOURCE: Lifshitz Law Firm